| Document |
Document Title |
|
WO/2013/007698 |
An anti-epileptic agent for use in the treatment of a neurological disorder other than epilepsy characterised in that the anti-epileptic agent is the sole active agent and that the daily dose of the anti-epileptic is less than 20% of the...
|
|
WO/2013/009981 |
Provided herein are methods of treating a neurological disease or injury in a subject comprising administering to the subject a recombinant adeno-associated virus (rAAV) vector comprising a DRP1-encoding nucleic acid, wherein the DRP1 en...
|
|
WO/2013/007676 |
The invention relates to JNK inhibitors and corresponding methods, formulations, and compositions for inhibiting JNK and treating JNK-mediated disorders. The application discloses JNK inhibitors, as described below in Formula (I): wherei...
|
|
WO/2013/009810 |
Disclosed is a method of treating a neurodegenerative disease or disorder by administering a compound having the formula (I): wherein X1; X2, X3, R1, R2, R3, R4, Y, A, Z, L and n are as defined herein.
|
|
WO/2013/010176 |
This invention relates, e.g., to a method for designing or selecting on a computer a candidate small molecule amyloid binder or inhibitor, comprising: a) docking test compounds to the binding site or binding surface determined from the t...
|
|
WO/2013/008044 |
The current invention covers the synthesis of (+) and (-) l-(5,5-diphenyItetrahydrofuran-3- yl)-N,N-dimethylmethanamine [(±)1] and [(-)1] respectively, including their pharmacologically acceptable acid addition salts. The new products c...
|
|
WO/2013/009812 |
Disclosed is a method of treating a neurodegenerative disease or disorder or a B- cell lymphoma by administering a compound having the formula:(I) wherein X1; X2, X3, R1, R2, R3, R4, Y, A, n and L are as defined herein.
|
|
WO/2013/009259 |
The present invention relates to novel chemical compounds formula (I) (C)n-B-(A)m-B-(C)n (I) wherein m is 0 or 1, and n is independently 0, 1, 2 or 3, A, each B and each C are independently selected from phenylene and five-and six-member...
|
|
WO/2013/009647 |
The invention provides compounds of formula (I): (I) or salts thereof, wherein R1, R2, R3 Z, and X have any of the values defined herein, as well as compositions comprising such compounds. The compounds and compositions are useful for tr...
|
|
WO/2013/006978 |
Isolated polypeptides are disclosed herein, the isolated polypeptides comprising at least 90% identity to any one of: SEQ ID NO:1; SEQ ID NO:2; or SEQ ID NO:3, wherein the isolated polypeptide inhibits an interaction between palmitoyl ac...
|
|
WO/2013/010176 |
This invention relates, e.g., to a method for designing or selecting on a computer a candidate small molecule amyloid binder or inhibitor, comprising: a) docking test compounds to the binding site or binding surface determined from the t...
|
|
WO/2013/009186 |
The present invention relates to compositions and methods for the prophylaxis or treatment of deficiencies in essential amino acid absorption and metabolism and/or of a pathology or symptom associated there with. In particular the invent...
|
|
WO/2013/009981 |
|
|
WO/2013/009517 |
A dual H1/5-HT2A receptor antagonist of the formula:, its uses, and methods for its preparation are described.
|
|
WO/2013/009830 |
Disclosed is a method of treating a B-cell lymphoma by administering a compound having the formula wherein X1; X2, X3, R1, R2, R3, R4, Y, A, Z, L and n are as defined herein.
|
|
WO/2013/007621 |
The present invention relates to compounds of formula (I) useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said compounds. The compounds referred to are positi...
|
|
WO/2013/007663 |
The invention relates to compounds that act as selective glycogen synthase kinase 3 (GSK-3) ligands and can be used for the treatment of GSK-3-mediated diseases. The compounds of the invention act as glycogen synthase kinase 3 (GSK-3) in...
|
|
WO/2013/007986 |
The invention provides orvinol and thevinol compounds useful for the treatment of drug and alcohol abuse, the compounds being particularly useful for the prevention of relapse in recovering addicts.
|
|
WO/2013/009543 |
The present invention relates to novel polycyclic pyrrolidine-2, 5-dione derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators the N-formyl pe...
|
|
WO/2013/007874 |
The present invention relates to the fields of knockout (KO) animal production. The invention is directed to a transgenic KO animal comprising a heterozygous or homozygous deletion or functional deletion of the gene's native 3' untransla...
|
|
WO/2013/010132 |
Methods for preventing or treating pain are provided. Such methods comprise administering to a subject (e.g., a human subject) an antibody or antibody fragment that binds LPA. The antibody may be a humanized monoclonal antibody.
|
|
WO/2013/008093 |
The present application provides terpene analogues of Formula 1 and methods and uses thereof for treating neurological conditions such as pain in general and neuropathic pain specifically.(Formula I) (I) wherein: Y is a C1 to C20 alkylen...
|
|
WO/2013/007381 |
The present invention relates to a pharmaceutical composition containing apomorphine as the active pharmaceutical ingredient, co-solvent, antioxidant, water having a pH greater than 4. The pharmaceutical formulation is suitable for paren...
|
|
WO/2013/004984 |
There is provided compounds of formula (I), wherein R1, R2, X, R3 and R4 have meanings given in the description (and which compounds are optionally substituted as indicated in the description), and pharmaceutically-acceptable esters, ami...
|
|
WO/2013/004249 |
The present invention relates to the combined use of compounds which are activators of the KCNQ family potassium ion channels and compounds which are serotonin 5- HT1 receptor agonists. The combined use of KCNQ channel activators and 5-H...
|
|
WO/2013/004995 |
The present invention provides compounds of formula (1) and pharmaceutically acceptable salts thereof, wherein R1, R2, Y and Z are as defined in the specification, processes for their preparation, pharmaceutical compositions containing t...
|
|
WO/2013/006400 |
Disclosed are novel compounds having the structure of Formula (I) : which are useful for treating mammals for dependence upon substances of addiction, for example addiction to a dopamine-producing agent such as cocaine, morphine, ampheta...
|
|
WO/2013/004145 |
Provided are a composition of a Chinese medicinal compound or extract and a use thereof. The Chinese medicine consists of ginseng, coptis, and gardenia. Also provided is a use of the composition in preparing a medicament for treating or ...
|
|
WO/2013/005755 |
A compound represented by formula (IA) or a pharmaceutically acceptable salt thereof, which acts relying on an orexin (OX) receptor antagonistic activity and is useful for the treatment or prevention of diseases such as sleep disorder, d...
|
|
WO/2013/004527 |
The present invention relates to the treatment of Alzheimer's disease and type 2 diabetes mellitus by a small molecule changing the activity of IDE. The molecule of the invention binds to the exosite of insulin degrading enzyme. Therefor...
|
|
WO/2013/004556 |
The present invention relates to the treatment of Alzheimer's disease and type 2 diabetes mellitus by a small molecule changing the activity of IDE. The molecule binding to the exosite of insulin degrading enzyme accelerates amyloid-β c...
|
|
WO/2013/005354 |
The present invention provides: a heterocyclic derivative having an excellent inhibitory activity on the production of amyloid-β; and use of the heterocyclic derivative. A compound represented by formula (I) (wherein each symbol is as d...
|
|
WO/2013/004995 |
The present invention provides compounds of formula (1) and pharmaceutically acceptable salts thereof, wherein R1, R2, Y and Z are as defined in the specification, processes for their preparation, pharmaceutical compositions containing t...
|
|
WO/2013/004617 |
The present invention relates to compounds useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said com- pounds. The compounds referred to are positive allosteric...
|
|
WO/2013/005798 |
A PDE10 inhibitor having excellent effectiveness, particularly a prophylactic or therapeutic agent for mental diseases such as schizophrenia and the like, has been demanded. The present invention provides: a nitrogenated heterocyclic rin...
|
|
WO/2013/006076 |
The invention provides a method of treatment of Alzheimer's disease and other neurodegenerative diseases comprising intranasally administering Hsp70 protein and/or active fragments and/or derivatives thereof.
|
|
WO/2013/005094 |
Disclosed is an acid addition salt of donepezil, wherein acid counterion is selected from the group consisting of pamoic acid, cypionic acid, camphor sulfonic acid, enanthic acid, fusidic acid, gluceptic acid, gluconic acid, lactobionic ...
|
|
WO/2013/006758 |
The present invention provides compounds of Formulae (I)-(V), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. In one aspect, compounds of the present invention are useful as glycosyltransferase inhibit...
|
|
WO/2013/005017 |
The present invention relates to cannabinoids for use in the prevention or treatment of neurodegenerative diseases or disorders. Preferably the cannabinoids are cannabichromene (CBC) cannabidivarin (CBDV) and / or cannabidivarin acid (CB...
|
|
WO/2013/004399 |
The invention provides ultra-small peptide inhibitors that are capable of preventing amyloid formation/amyloidosis.
|
|
WO/2013/004642 |
The present invention relates to a compound of formula (IA) The present invention also relates to the use of the compound of formula IA for treating certain neurodegenerative disorders characterized by cytotoxic TAU misfolding and/or agg...
|
|
WO/2013/004740 |
The present invention relates to the anticonvulsant activity of turmeric oil and its volatile bisabolene sesquiterpenoids ar- turmerone, α-turmerone, β-turmerone (curlone) and α- atlantone, as an anticonvulsant agent for the treatment...
|
|
WO/2013/005108 |
The present invention relates to compositions and methods for treatment of neurological disorders. In particular, the present invention relates to EGFR as a clinical target for treatment of neurological disorders.
|
|
WO/2013/004177 |
Disclosed is a composition of an active ingredient of traditional Chinese medicine, comprising geniposide or jasminoidin, berberine, total saponins of panax ginseng or a composition of ginsenoside monomer. Also disclosed is the use of th...
|
|
WO/2013/006020 |
The present invention relates to a composition for protecting nerve cells, and to a functional health food, which comprise pyruvic acids or pharmaceutically acceptable salts thereof so as to inhibit nerve cell apoptosis caused by ethanol...
|
|
WO/2013/004557 |
The present invention relates to the treatment of Alzheimer's disease and type 2 diabetes mellitus by a small molecule changing the activity of insuline degrading enzyme (IDE). The molecule of the invention binds to the exosite of insuli...
|
|
WO/2013/004996 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 is hydrogen or fluorine, one of A and B is R2, the other is a group -X-Y-R3. R3 represents a carbocyclic or heterocyclic ri...
|
|
WO/2013/006569 |
Provided herein are, inter alia, vaccines and methods of using the same for the treatment or prevention of Herpesvirus infections.
|
|
WO/2013/004525 |
The present invention relates to the treatment of Alzheimer's disease and type 2 diabetes mellitus by a small molecule changing the activity of IDE. The molecule of the invention binds to the exosite of insulin degrading enzyme. Therefor...
|
|
WO/2013/000395 |
Disclosed in the present invention is a novel histone deacetylase inhibitor of benzamides and use thereof; the inhibitor has good efficacy in treating diseases caused by abnormal gene expression, such as tumours, endocrine disorders, imm...
|
